Literature DB >> 10332684

Contribution of postprandial versus interprandial blood glucose to HbA1c in type 1 diabetes on physiologic intensive therapy with lispro insulin at mealtime.

M Ciofetta1, C Lalli, P Del Sindaco, E Torlone, S Pampanelli, L Mauro, D L Chiara, P Brunetti, G B Bolli.   

Abstract

OBJECTIVE: To quantitate the contribution of postprandial blood glucose, which improves with the short-acting insulin analog lispro [Lys(B28),Pro(B29)] in type 1 diabetes, to the overall 24-h blood glucose concentration and the long-term HbA1c concentration under conditions of different postabsorptive blood glucose. RESEARCH DESIGN AND METHODS: A total of 24 type 1 diabetic patients on long-term intensive therapy with premeal human regular insulin (Hum-R) and bedtime NPH were randomly assigned to a continuation of Hum-R (group 1, n = 8), lispro (group 2, n = 8), or lispro + NPH (in variable proportions) administered at mealtime (group 3, n = 8) for 3 months, NPH administered at bedtime was continued in all three groups. Data from home blood glucose monitoring were collected, and a 24-h plasma glucose and insulin profile was obtained during a 2-day hospital visit to calculate areas under the postprandial glucose curve (3.5 h after breakfast, 3.5 h after lunch, and 3.0 h after dinner for a total of 10.0 h) and the postabsorptive blood glucose curve (the remaining 14.0 h out of 24.0 h) (AUC). Eight nondiabetic subjects were also studied.
RESULTS: The substitution of Hum-R with lispro (group 2) resulted in lower postprandial blood glucose, but greater postabsorptive blood glucose (P < 0.05 vs. group 1). The postprandial blood glucose AUC was lower (161 +/- 19 vs. 167 +/- 20 mg.100 ml-1.h-1), but the postabsorptive blood glucose AUC was greater (155 +/- 22 vs. 142 +/- 19 mg.100 ml-1.h-1) (P < 0.05). Therefore, the 24-h blood glucose AUC was no different (NS). Consequently, HbA1c was no different (NS). This occurred because in group 2, mealtime lispro resulted in normal prandial plasma insulin, but also resulted in lower interprandial concentration (P < 0.05 vs. group 1). When NPH was added to lispro (30% at breakfast, 40% at lunch, 10% at dinner) in group 3, postabsorptive plasma insulin was similar to group 1 (NS), in group 3, the postprandial blood glucose AUC (153 +/- 17 mg.100 ml-1.h-1) was lower and the postabsorptive blood glucose AUC was no different, as compared with group 1 (NS). Therefore, the 24-h blood glucose AUC was lower (147 +/- 17 vs. 155 +/- 21 and 158 +/- 20 mg.100 ml-1.h-1), and HbA1c was lower (6.41 +/- 0.12 vs. 6.84 +/- 0.2 and 6.96 +/- 0.2% (groups 3, 1, and 2 respectively, P < 0.05). Frequency of hypoglycemia was greater in group 2 (P < 0.05), but not in group 3 (NS) vs. group 1.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10332684     DOI: 10.2337/diacare.22.5.795

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  12 in total

Review 1.  Treatment and prevention of hypoglycemia and its unawareness in type 1 diabetes mellitus.

Authors:  Geremia B Bolli
Journal:  Rev Endocr Metab Disord       Date:  2003-12       Impact factor: 6.514

2.  Continuous subcutaneous insulin infusion versus multiple daily injections.

Authors:  P Karagianni; Ch Sampanis; Ch Katsoulis; Gr Miserlis; S Polyzos; I Zografou; S Stergiopoulos; I Douloumbakas; Ch Zamboulis
Journal:  Hippokratia       Date:  2009-04       Impact factor: 0.471

3.  Meta-analysis of short-acting insulin analogues in adult patients with type 1 diabetes: continuous subcutaneous insulin infusion versus injection therapy.

Authors:  A Siebenhofer; J Plank; A Berghold; K Horvath; P T Sawicki; P Beck; T R Pieber
Journal:  Diabetologia       Date:  2004-11-25       Impact factor: 10.122

Review 4.  Insulin lispro: a review of its use in the management of diabetes mellitus.

Authors:  Dene Simpson; Paul L McCormack; Gillian M Keating; Katherine A Lyseng-Williamson
Journal:  Drugs       Date:  2007       Impact factor: 9.546

5.  Prevalence and correlates of post-prandial hyperglycaemia in a large sample of patients with type 2 diabetes mellitus.

Authors:  E Bonora; G Corrao; V Bagnardi; A Ceriello; M Comaschi; P Montanari; J B Meigs
Journal:  Diabetologia       Date:  2006-03-11       Impact factor: 10.122

6.  Efficacy and safety of insulin analogues for the management of diabetes mellitus: a meta-analysis.

Authors:  Sumeet R Singh; Fida Ahmad; Avtar Lal; Changhua Yu; Zemin Bai; Heather Bennett
Journal:  CMAJ       Date:  2009-02-17       Impact factor: 8.262

7.  Modeling Pharmacokinetic Profiles of Insulin Regimens to Enhance Understanding of Subcutaneous Insulin Regimens.

Authors:  Lai San Tham; Karen Schneck; Ali Ertekin; Jesus Reviriego
Journal:  J Clin Pharmacol       Date:  2017-04-10       Impact factor: 3.126

Review 8.  A Review of Basal-Bolus Therapy Using Insulin Glargine and Insulin Lispro in the Management of Diabetes Mellitus.

Authors:  Riccardo Candido; Kathleen Wyne; Ester Romoli
Journal:  Diabetes Ther       Date:  2018-04-13       Impact factor: 2.945

Review 9.  An estimation of the long-term clinical and economic benefits of insulin lispro in Type 1 diabetes in the UK.

Authors:  C Pratoomsoot; H T Smith; A Kalsekar; K S Boye; J Arellano; W J Valentine
Journal:  Diabet Med       Date:  2009-08       Impact factor: 4.359

Review 10.  Inhaled human insulin (Exubera): clinical profile and patient considerations.

Authors:  Anthony H Barnett; Sri Bellary
Journal:  Vasc Health Risk Manag       Date:  2007
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.